-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma partners with Sobi to license lacutamab in T-cell lymphoma for USD 75 million upfront

PUBT·08/10/2026 06:00:29
Listen to the news
Innate Pharma partners with Sobi to license lacutamab in T-cell lymphoma for USD 75 million upfront
  • Innate Pharma struck a strategic partnership with Sobi to advance lacutamab in T-cell lymphoma, targeting a Phase 3 confirmatory study in CTCL.
  • Innate will run the TELLOMAK-3 trial to support a planned accelerated approval filing in Sézary syndrome.
  • Sobi will get exclusive global commercialization rights upon potential accelerated approval, with an option to take full global development rights after positive Phase 3 results.
  • Sobi will pay USD 75 million at closing; Innate can earn up to USD 40 million in near-term development milestones tied to Sézary syndrome.
  • Deal includes up to USD 465 million in option, regulatory, and commercial milestones, with tiered double-digit royalties on net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260809916851) on August 10, 2026, and is solely responsible for the information contained therein.